首页> 外文期刊>Oncology reports >Significance of Lysyl oxidase-like 2 gene expression on the epithelial-mesenchymal status of hepatocellular carcinoma
【24h】

Significance of Lysyl oxidase-like 2 gene expression on the epithelial-mesenchymal status of hepatocellular carcinoma

机译:赖氨酰氧化酶样2基因表达对肝细胞癌上皮 - 间充质状态的意义

获取原文
获取原文并翻译 | 示例
           

摘要

In the present study, we investigated the role of lysyl oxidase-like 2 (LOXL2), the correlation between LOXL2 and epithelial to mesenchymal transition (EMT) and the effects of using beta-aminopropionitrile (BAPN) to inhibit LOXL2 with the aim of reducing tumor progression in hepatocellular carcinoma (HCC). The expression level of LOXL2 was evaluated in HCC and adjacent non-cancerous tissues using quantitative reverse transcription polymerase chain reaction and clinicopathological analyses. The effects of BAPN on cell proliferation, migration and invasion were investigated in vitro. Additionally, LOXL2 expression was assessed in the culture supernatants of HCC cell lines. Our results revealed that LOXL2 expression was higher in HCC cell lines and tissues. There was a significant correlation between EMT status and LOXL2 levels (P=0.004). BAPN reduced migration and invasion in HCC cells. HCC patients with high levels of LOXL2 expression had relatively shorter disease-free survival (P=0.009) and overall survival (P=0.035). The expression level of LOXL2 was similar between cell supernatants and HCC cell lines. A multivariate analysis demonstrated that portal vein invasion (P=0.015), venous invasion (P=0.026), serum AFP (alpha-fetoprotein) levels (P=0.019) and LOXL2 expression (P=0.009) were independent prognostic factors. Our results indicated that a higher level of LOXL2 may contribute to tumor progression, indicating that LOXL2 has clinical value as a therapeutic target in HCC.
机译:在本研究中,我们研究了溶酶样氧化酶样2(LOX12)的作用,LOX12之间的相关性和上皮对间充质转换(EMT)以及使用β-氨基丙腈(BAPN)的作用抑制LOXL2的目的肝细胞癌(HCC)中的肿瘤进展。使用定量逆转录聚合酶链反应和临床病理分析,在HCC和相邻的非癌组织中评价LOX12的表达水平。体外研究了BAPN对细胞增殖,迁移和侵袭的影响。另外,在HCC细胞系的培养上清液中评估LOXL2表达。我们的结果表明,HCC细胞系和组织中LOXL2表达更高。 EMT状态和LOXL2水平之间存在显着相关性(P = 0.004)。 BAPN降低了HCC细胞中的迁移和侵袭。 HCC患者高水平的LOX12表达具有相对较短的无病生存率(P = 0.009)和总存活(P = 0.035)。 LOX12的表达水平在细胞上清液和HCC细胞系之间类似。多变量分析证明了门静脉侵袭(P = 0.015),静脉侵袭(P = 0.026),血清AFP(α-胎儿蛋白)水平(P = 0.019)和LOXL2表达(P = 0.009)是独立的预后因素。我们的结果表明,较高水平的LOX12可能有助于肿瘤进展,表明LOX12具有作为HCC中治疗靶标的临床价值。

著录项

  • 来源
    《Oncology reports》 |2018年第6期|共9页
  • 作者单位

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

    Nagoya Univ Grad Sch Med Dept Gastroenterol Surg Nagoya Aichi 4668550 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    LOX; LOX family; LOXL2; epithelial-to-mesenchymal transition; hepatocellular carcinoma;

    机译:lox;lox家族;loxl2;上皮 - 间充质转换;肝细胞癌;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号